Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience

William C.N. Dunlop, Alexandra Staufer, Pierre Levy and Guy J. Edwards

Health Policy, 2018, vol. 122, issue 5, 528-532

Abstract: Innovative pricing agreements for medicines have been used in European markets for more than 20 years, and offer an opportunity for payers and pharmaceutical companies to align on value, optimise speed to patients, and share risk. Developing successful agreements requires alignment between key stakeholders, yet there is a lack of summative data on how current innovative agreements are used in the real-world (e.g. the level of realised access to medicines, and rebates and discounts, which are often non-transparent).

Keywords: Drug costs; Drug industry/economics; Drug industry/organization & administration; Risk sharing, financial; Innovative pricing agreements; Managed entry agreements (search for similar items in EconPapers)
Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (5)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851018300514
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:122:y:2018:i:5:p:528-532

DOI: 10.1016/j.healthpol.2018.02.008

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().